─ Cowen and Company 36th Annual
Health Care Conference ─
─ Barclays Capital Global Healthcare Conference ─
─ Webcasts Available Through Aimmune Corporate Website ─
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 1, 2016--
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that members of the senior management team will present a
company overview at the Cowen and Company 36th Annual Health
Care Conference on Tuesday, March 8, 2016, at 11:20 a.m. Eastern Time
and at the Barclays Capital Global Healthcare Conference on Wednesday,
March 16, 2016, at 4:20 p.m. Eastern Time.
The live webcasts of the presentations will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
The replays of the webcasts will be available for 14 days following each
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for peanut allergy and other
life-threatening food allergies. The company’s characterized oral
desensitization immunotherapy (CODIT™) system, an approach to oral
immunotherapy (OIT), uses rigorously characterized product candidates
with gradual, controlled up-dosing protocols to obtain clinically
meaningful desensitization to food allergens. Aimmune Therapeutics
initiated the Phase 3 PALISADE trial of its lead product, AR101, a
complex mixture of natural peanut proteins and pharmaceutical-grade
ingredients for the treatment of peanut allergy, one of the most common
food allergies, in early 2016. AR101 has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301005813/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,